Lister T A, Crowther D, Sutcliffe S B, Glatstein E, Canellos G P, Young R C, Rosenberg S A, Coltman C A, Tubiana M
Department of Medical Oncology, St Bartholomew's Hospital, London, England.
J Clin Oncol. 1989 Nov;7(11):1630-6. doi: 10.1200/JCO.1989.7.11.1630.
The Ann Arbor classification for describing the stage of Hodgkin's disease at initial presentation has formed the basis upon which treatment is selected and has allowed comparison of results achieved by different investigators for almost two decades. A meeting was convened to review the classification and modify it in the light of experience gained in its use and new techniques for evaluating disease. It was concluded that the structure of the classification be maintained. It was particularly recommended: (1) that computed tomography (CT) be included as a technique for evaluating intrathoracic and infradiaphragmatic lymph nodes; (2) that the criteria for clinical involvement of the spleen and liver be modified to include evidence of focal defects with two imaging techniques and that abnormalities of liver function be ignored; (3) that the suffix 'X' to designate bulky disease (greater than 10 cm maximum dimension) be introduced; and (4) that a new category of response to therapy, unconfirmed/uncertain complete remission (CR[u]), be introduced to accommodate the difficulty of persistent radiological abnormalities of uncertain significance.
用于描述霍奇金淋巴瘤初诊时分期的安阿伯分期法,构成了选择治疗方案的基础,并使得不同研究者所取得的结果能够在近二十年的时间里进行比较。召开了一次会议,以根据该分期法在使用过程中积累的经验以及评估疾病的新技术,对其进行审查和修改。会议得出结论,应保持分期法的结构。特别建议:(1)将计算机断层扫描(CT)纳入评估胸内和膈下淋巴结的技术;(2)修改脾脏和肝脏临床受累的标准,将两种成像技术显示的局灶性缺损证据纳入其中,而忽略肝功能异常;(3)引入后缀“X”以表示大包块疾病(最大直径大于10厘米);(4)引入一种新的治疗反应类别,即未经证实/不确定的完全缓解(CR[u]),以应对意义不确定的持续性放射学异常所带来的难题。